ABSTRACT
The objective of this study was to generate a liver targeting fusion interferon, galactosyl-human serum albumin-interferon alpha2b (G-HSA-IFN) and to evaluate its bioactivity in vitro on HepG2.2.15 cells which express hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg). The cell proliferation was determined by Sulpho Rhodamine B (SRB) staining method and flow cytometry (FCM) assay. Hochest33342 and Propidium Iodide (PI) double staining and Western blot analysis of Bcl-2/Bax were also performed to evaluate cell lethality and apoptosis. The concentrations of HBsAg and HBeAg secreted in culture supernatant were detected using Enzyme-Linked Immunosorbent Assay (ELISA). The results demonstrated that G-HSA-IFN could inhibit the proliferation of HepG2.2.15 cells and the cell cycle was arrested at G0/G1 phase. Western blotting results showed that the expression of Bcl-2 was inhibited in a dose-dependent manner while the expression of Bax was enhanced. The expression of HBsAg was inhibited by G-HSA-IFN in a dose-dependent manner, while no significant inhibiting effect on the expression of HBeAg was observed. Conclusively, G-HSA-IFN could not only significantly inhibit the HBsAg expression and the proliferation of HepG2.2.15 cells, but also induce the apoptosis of the target cells, rendering it a promising drug candidate for hepatitis B.
Subject(s)
Antiviral Agents/administration & dosage , Antiviral Agents/pharmacokinetics , Drug Delivery Systems , Interferon-alpha/administration & dosage , Interferon-alpha/pharmacokinetics , Liver/metabolism , Antiviral Agents/pharmacology , Apoptosis/drug effects , Blotting, Western , Cell Cycle/drug effects , Cell Death/drug effects , Cell Line , Cell Proliferation/drug effects , Enzyme-Linked Immunosorbent Assay , Hepatitis B Surface Antigens/analysis , Hepatitis B Surface Antigens/biosynthesis , Hepatitis B e Antigens/analysis , Hepatitis B e Antigens/biosynthesis , Humans , Interferon-alpha/pharmacology , Liver/drug effects , Microscopy, Fluorescence , S Phase/drug effectsABSTRACT
OBJECTIVE: To investigate the effect of betulinic acid (BA) on the proliferation, migration, apoptosis and cell cycle of pancreatic cancer cells (BxPC-3) in vitro and elucidate the underlying. METHOD: The effect of BA on the proliferation of BxPC-3 was measured by using sulforhodamine B (SRB) assay. Migratory ability of BxPC3 cells were detected by wound healing assay, and the morphological change was observed with light microscope. The influence of BA on cell cycle of BxPC-3 cells was tested by flow cytometry (FCM). Apoptosis was analyzed by using Hochest33342-PI double staining. Western blot technologies were applied to detect the expression of Bcl-2 and Bax. RESULT: BA exhibited significant cell proliferation and migration inhibition, as well as its potency of inducing apoptosis in BxPC-3 cells in vitro in a dose-dependent manner. The IC50 value for 72 h was 16.54 mg x L(-1). Cell migration was significantly inhibited at 5 mg x L(-1) of BA. Cells treated with BA showed increased cell population in G0 phase, with decreased G2/M phase population. The expression of Bax and Bcl-2 was up and down-regulated respectively in BA-treated BxPC-3 cells in a dose-dependent manner. CONCLUSION: BA exerted potent effect on growth inhibition, G0 cell cycle arrest and induction of apoptosis in BxPC-3 cells in vitro, possibly associated with the down-regulation of Bcl-2 and up-regulation of Bax expression. The potent antitumor capacity of BA suggested that it could be a promising new anticancer agent in human pancreatic cancer treatment.
Subject(s)
Apoptosis/drug effects , Cell Cycle/drug effects , Cell Proliferation/drug effects , Drugs, Chinese Herbal/pharmacology , Pancreatic Neoplasms/physiopathology , Triterpenes/pharmacology , Cell Line, Tumor , Cell Movement/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Humans , Pancreatic Neoplasms/drug therapy , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/metabolism , Pentacyclic Triterpenes , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , bcl-2-Associated X Protein/genetics , bcl-2-Associated X Protein/metabolism , Betulinic AcidABSTRACT
In the title compound, C(9)H(9)FO(3), the dihedral angle between the carboxyl group and the benzene ring is 79.4â (3)°. In the crystal, mol-ecules form centrosymmetric dimers through pairs of classical O-Hâ¯O hydrogen bonds. These are further linked by weaker C-Hâ¯O inter-actions, forming a three-dimensional network.
ABSTRACT
The title mol-ecule, C(13)H(18)N(2)O(3), contains a benzene ring fused to an oxazine ring and one tert-but-oxy-carbonyl group bound to the N atom of the oxazine ring. A weak intra-molecular C-Hâ¯O inter-action occurs. In the crystal, inter-molecular N-Hâ¯O and C-Hâ¯O hydrogen bonds stack the mol-ecules down the b axis. Weak C-Hâ¯N contacts connect the stacks, generating a three-dimensional network.
ABSTRACT
The antiviral activity and biodistribution of a glycosylated fusion interferon directed to hepatic receptors were evaluated to determine whether its pharmaceutical concentration in the liver could be improved. The novel glycosylated fusion interferon, galactosyl-human serum albumin-interferon-alpha2b (G-HSA-IFN) was obtained from a long-term recombinant fusion protein (HSA-IFN) by covalent coupling with a bifunctional reagent, 2-imino-2-ethyloxymethy1-1-thiogalactose. There are about 24 thiogalactose residues in each G-HSA-IFN molecular on average. The antiviral activities of IFNalpha2b, HSA-IFN, and G-HSA-IFN were compared in a cytopathic effect inhibition assay with the WISH/VSV system in vitro, and the modification had little effect on its antiviral activity. Both G-HSA-IFN and HSA-IFN were labeled with 125I and the radiochemical purity of 125I-G-HSA-IFN was greater than 96%. 125I-G-HSA-IFN bound to the asialoglycoprotein receptor (ASGP-R) on hepatic cells much more specifically than 125I-HSA-IFN, with specific binding rates of 89.53% and 6.66%, respectively (p < 0.01). Biodistribution research in mice showed that 125I-G-HSA-IFN could concentrate effectively in the liver (>45%/g) and suggested that it also could be a good imaging agent of hepatic receptors.
Subject(s)
Antiviral Agents/chemical synthesis , Hepatocytes/metabolism , Interferon-alpha/chemical synthesis , Recombinant Fusion Proteins/chemical synthesis , Animals , Antiviral Agents/chemistry , Antiviral Agents/pharmacology , Cell Line , Female , Glycosylation , Humans , In Vitro Techniques , Interferon alpha-2 , Interferon-alpha/chemistry , Interferon-alpha/pharmacology , Male , Mice , Mice, Inbred ICR , Protein Binding , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/pharmacology , Recombinant Proteins , Serum Albumin/chemistry , Tissue Distribution , Vesiculovirus/drug effectsABSTRACT
AIM: To study the inhibitory effect of 23-HBA on angiogenesis in vitro. METHODS: The effect of 23-hydroxy butulinic acid (23-HBA) on the in vitro proliferation of human microcapillary endothelial cells(HMECs) was examined by sulfonylrhodamine B (SRB) assay. The effect of 23-HBA on endothelial cell migration, and tubule formation on Matrigel was also observed. The CD31 expression in HMECs was dectected by immunohistochemical staining. RESULTS: The proliferation of HMECs was inhibited significantly by 23-HBA with IC(50) being 40.44 mg/L. 23-HBA inhibited endothelial cell migration and tubule formation in a dose-dependent manner. The expression of CD31 in HMECs was reduced after treatment with 10 mg/L 23-HBA. CONCLUSION: 23-HBA can inhibit angiogenesis in vitro, which would become a promising antiangiogenic drug.
